GlobeNewswire

In-Memory Computing Summit Europe 2018 Delivers Insights, Practical Advice for Addressing Digital Transformation Performance Challenges

Dela

Keynotes, Breakout Session from Industry Leaders and Technology Experts Offer Vital Guidance on Trends, Challenges and Solutions Across Diverse Industries

FOSTER CITY, Calif., July 02, 2018 (GLOBE NEWSWIRE) -- GridGain® Systems, provider of enterprise-grade in-memory computing platform solutions based on Apache® Ignite(TM), today discussed the success of the second annual In-Memory Computing Summit® Europe, which took place June 25-26, 2018 at the Park Plaza Victoria London. The In-Memory Computing Summits (IMCSs), held annually in Europe and North America, are the only industry-wide events focusing on the full range of in-memory computing technologies and solutions. More than 300 people representing 190 organizations from 22 countries on 4 continents registered for the conference to hear speakers from 451 Research, CG Consultancy, FSB Technology, ScaleOut Software, the Storage Networking Industry Association (SNIA), GridGain Systems and many more, explore key developments related to in-memory computing technology, describe the application performance benefits of the technology, and offer practical advice on a variety of in-memory computing topics.

"This year's IMC Summit Europe was a tremendous success, providing vital information for attendees looking to leverage in-memory computing to accelerate their organizations' digital transformation and omnichannel customer experience initiatives," said Terry Erisman, Vice President of Marketing, GridGain Systems. "The spirit of community and sharing at these events deepens our understanding of the technology, drives innovation, encourages partnerships, and enables attendees to help their organizations better meet the needs of their customers and end users. I want to thank our speakers, sponsors and attendees for their enormous contributions."

More than 30 industry leaders delivered six keynote addresses and 35 breakout sessions. The In-Memory Computing Summit Keynotes included:

  • "In-Memory Computing - Unlocking the Digital Future" by Abe Kleinfeld, President & CEO, GridGain Systems, who discussed the competitive advantage gained by early adopters of in-memory computing technology.
  • "Embracing the Service Consumption Shift in Banking" by David Follen, Chapter Lead at ING Belgium, who recounted how ING is using in-memory computing platforms to enable the organization to meet the rapidly changing demands of its customers.
  • "In-Memory Computing and Sports Betting" by Sam Lawrence, Co-founder and CTO, FSB Technology (UK) Ltd., who offered a personal look at the technical challenges the sports betting industry has faced and the solutions implemented at FSB Tech.
  • "Persistent Memory, NVM Programming Model, and NVDIMMs" by Alex McDonald, Director and Vice Chair at SNIA Europe, who described how the SNIA Non Volatile Memory Technical Work Group is delivering specifications describing the behavior of a common set of software interfaces that provide access to non-volatile memory, and how hardware and OSes support persistent memory today.
  • "In-Memory Computing: Accelerating the Data Behind Digital Business and the Customer Experience" by Matt Aslett, Research Director, 451 Research, who described how organizations are increasingly using in-memory computing technologies to create hybrid operational/analytic processing (HOAP) systems to address digital transformation.
  • "In-Memory Computing Driving the Digital Enterprise: A Panel Discussion" with William Bain, CEO, ScaleOut Software; Chris Goodall, Director, CG Consultancy (UK) Ltd; Sam Lawrence, Co-founder and CTO, FSB Technology (UK) Ltd; Tim Wood, Head, HPC and Model Integration at ING Financial Markets; and Matt Aslett, Research Director at 451 Research. The panelists discussed the current and future impact of in-memory computing on the digital enterprise.

The breakout session video recordings and slides will be available on the In-Memory Computing Summit Europe 2018 website.

Sponsors 
The In-Memory Computing Summit Europe 2018 was sponsored by leading technology vendors, including:

  • Platinum Sponsor - GridGain Systems
  • Gold Sponsor - ScaleOut Software
  • Silver Sponsors - Neeve Research, GridFore
  • Association Sponsors - Storage Networking Industry Association (SNIA), Apache Software Foundation
  • Media Sponsors - Digitalisation World, Enterprise Times, IT for CEOs & CFOs, IT Pro, ITR TV, Jet Info, ODBMS.org, Open Systems, Rusbase

The Next IMC Summit
The fourth annual In-Memory Computing Summit North America will take place October 2-3, 2018 at the Hyatt Regency San Francisco Airport. The Call for Speakers for the In-Memory Computing Summit North America 2018 will end on July 3, 2018.

About the In-Memory Computing Summit
The In-Memory Computing Summits in Europe and North America are the only industry-wide events tailored to in-memory computing-related technologies and solutions. They are the perfect opportunity to connect with technical IT decision makers, IT implementers, and developers who make or influence purchasing decisions in the areas of in-memory computing, Big Data, Fast Data, IoT and HPC. Attendees include CEOs, CIOs, CTOs, VPs, IT directors, IT managers, data scientists, senior engineers, senior developers, architects and more. The Summits are unique forums for networking, education and the exchange of ideas - ideas that power the new world and future of Fast Data. For more information, visit https://imcsummit.org and follow the event on Twitter @IMCSummit.

About GridGain® Systems
GridGain Systems is revolutionizing real-time data access and processing by offering an in-memory computing platform built on Apache® Ignite(TM). GridGain solutions are used by global enterprises in financial, software, e-commerce, retail, online business services, healthcare, telecom and other major sectors, with a client list that includes Barclays, ING, Sberbank, Finastra, IHS Markit, Workday, and Huawei. The GridGain in-memory computing platform delivers unprecedented speed and massive scalability to both legacy and greenfield applications. Deployed on a distributed cluster of commodity servers, GridGain software can reside between the application and data layers (RDBMS, NoSQL and Apache® Hadoop®), requiring no rip-and-replace of the existing databases, or it can be deployed as an in-memory transactional SQL database. GridGain is the most comprehensive in-memory computing platform for high-volume ACID transactions, real-time analytics, web-scale applications, artificial intelligence, and continuous learning and HTAP. The GridGain Cloud is a hosted in-memory computing solution for use cases that require powerful yet very easy-to-deploy solutions with SQL support. For more information, visit gridgain.com.

CONTACT:
Terry Erisman
GridGain Systems
terisman@gridgain.com
(650) 241-2281

GridGain and the In-Memory Computing Summit are trademarks or registered trademark of GridGain Systems, Inc. Apache, Apache Hadoop, Hadoop, Apache Ignite, and Ignite are trademarks of The Apache Software Foundation. All other product and company names herein may be trademarks of their registered owners. 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: GridGain Systems via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum